Dr. Steve Yu
Senior Vice President
and Senior Scientist
Dr. Steve Yu has more than 20 years of experience in the field of genetically modified animal models
from both R&D and management roles. As an internationally renowned expert in model animals and cell
biology, Dr. Yu successively served in Yale School of Medicine and NYU Grossman School of Medicine,
inGenious Targeting Laboratory (iTL), Applied StemCell (ASC) and other institutions in the field of
genetically modified animal models. Currently, Dr. Yu is working for Cyagen as Senior Vice President
and Senior Scientist, primarily responsible for the technical development of genetically modified
animal model platforms. His research results have been published in high-impact journals such as
Nat Immunol and Mol Cell Biol.
Dr. Marvin Ouyang
Executive Vice President
and Chief Scientific Officer
Dr. Marvin Ouyang has been dedicated to the development of genetically engineered rodent models for
the past 20 years, developing hundreds of transgenic and KO/KI mouse/rat models for biomedical
research and drug development. Previously, he served as the senior scientist of Oklahoma Medical
Research Foundation (OMRF), a scientist for U.S.-based Thios Pharmaceuticals , and worked for
Taconic Biosciences as the leader of the Molecular Biology Department. So far, he has published many
papers in high-impact academic journals such as PNAS and JBC. Technical services developed by Dr.
Ouyang have been directly cited hundreds of times by top international journals, including Nature.
Dr. Rongli Zhang
Chief Scientist of Cyagen
Surgical Disease Models
Dr. Rongli Zhang has more than 20 years of experience in creating mouse surgical models. Prior to
Cyagen, Dr. Zhang was employed by China Academy of Chinese Medical Science (CACMS), Tsinghua
University (THU), Peking University (PKU) and other internationally renowned academic institutions
after earning his PhD. Since 2011, he has worked in Case Western Reserve University in the U.S. as
both a research scientist and as director of the Cardiovascular Physiology Laboratory, where he
leads the discovery of disease phenotypes in genetically engineered animals and preclinical drug
development. In addition, he has done many preclinical pharmacology studies for domestic and
worldwide pharmaceutical enterprises - helping these companies achieve successful product launches.
Dr. Zhang has finished 10 projects during his work in China and took part in multiple fund programs
in the U.S. supported by both the NIH (National Institutes of Health) and AHA (American Heart
Association). He has 60 publications in SCI journals, with many articles published in high-impact
academic journals (such as
Nature, Proceedings of the National Academy of Sciences, Journal of Clinical Investigation,
Circulation, Cell, Nature Communications,
and Science Translational Medicine).